

## Bijlage 1: FISH Probelijst Enschede

Nr.	Probenaam	Indicatie	locus	Gen	Leverancier	Werk	Verdunning
65	LSI ABL SO/BCR SG ES	CML/ALL	9q34 (so)/22q11.2 (sg)	BCR-ABL	Vysis	tumor	1;9
67	FGFR1-cyto	MPN	8p11.2	FGFR1	Kreatech/Leica	tumor	onverdund
68	LSI CFBF(inv 16) SR/SG DC break apart	AML M4	16q22	CBFB	Vysis	tumor	1;9
69	ETV6/RUNX1-DC ES cyto	ALL	12p13 (sg)/21q22 (so)	ETV6/RUNX1	Vysis	tumor	1;9
70	D13S319(13q14) (so)	HEMA	del(13q14) (so)	D13S319	Vysis	tumor	1.9
71	LSI IGH/CCND1-XT	MM	IGH (sg)14q32 /CCND1-XT(so)11q13	IGH/CCND1	Vysis	tumor	1.9
72	BCR/ABL DCDF t(9;22)	CML/ALL	9q34 (so)/22q11.2 (sg)	ABL/BCR	Vysis	tumor	1.9
73	LSI MLL SO/SG DC	ALL/AML	11q23	MLL	Vysis	tumor	1;9
74	RUNX1-RUNX1T1	AML M2	8q22 (so)/21q22 (sg)	RUNX1T1/RUNX1	Vysis	tumor	1;9
75	LSI p53/ATM,	cll	17p13.1 (so)/11q22.3 (sg)	P53/ATM	Vysis	tumor	1;1
76	BCR/ABL +9q34 tricolore DF	CML/ALL	9q34 (so/sa)/22q11.2 (sg)	ABL/ASS/BCR	Vysis	tumor	1;9
78	LSI EGR1 SO/D5S721,D5S23 SG	MDS/AML	5q31 (so)/5p15.2 (sg)	EGR1	Vysis	tumor	1;9
79	LSI IGH SO/SG DC	lymfatische aandoening	14q32	IGH	Vysis	tumor	1;9
80	ONDEK/NUP214 t(6;9)	AML	6p22(DEK) (sg)/9q34(NUP214) (so)	DEK/NUP214	Kreatech/Leica	tumor	onverdund
81	LSI TP53(17p13.1)	MM	LSI TP53 (17p13.1) (SO)	TP53	Vysis	tumor	1;9
82	IGH/MYC/cep8 tricolor DF	BL tri 8	IGH (sg)14q32/ myc (so)/8q24 cep 8(sa)	IGH/MYC/centr.8	Vysis	tumor	1;9
83	LSI D5S23/D5S721/CEP9/CEP15	MM	D5s23/D5s721(sg)/cep9 (sa)/cep15(so)	D5S23,D5S721/centr.9/centr.15	Vysis	tumor	1;9
85	ATM (11q22.3)	CLL	11q22.3 (sg)	ATM	Vysis	tumor	1.9
86	LSI-IGH SG/FGFR3 SO DC,DF t(4;14)	MM	14q32 (sg)/4p16.3 (so)	IGH-FGFR	Vysis	tumor	1;9
87	LSI IGH/MAF DC DF t(14;16)	MM	IGH (sg)14q32 /MAF(so)16q23	IGH/MAF	Vysis	tumor	1;9
88	D7S486/cep7 fish probekit	MDS/AML	D7S486 (so)/cep7 (sg)fish probekit	D7S486/centr.7	Vysis	tumor	1;9
89	LSI D20S108 SO	MDS	20q12 (so)	D20S108	Vysis	tumor	1;9
90	CKS1B/CDKN2C 1p/1q	MM	1q21 (so)/1p32.3 (sg)	CKS1B/CDKN2C	aqaurius Cytocell	tumor	onverdund
91	LSI IGH SG/BCL2 SO DC,DF,Trans	Lymfoom	14q32 (sg)/18q21 (so)	IGH-BCL2	Vysis	tumor	1;9
92	LSI PML so/RARA sg DC,DF t(15;17)	AML M3	15q22-24 (so)/17q21.1 (sg)	PML-RARA	Vysis	tumor	1;9
93	LSI D13(RB1) so	MM	13q14 (so)	RB1	Vysis	tumor	1;9
94	ETV6 DC break apart	AML/MDS/MPN/ALL	12p13	ETV6	Vysis	tumor	1.9
95	LSI 13 (13q14) sg	MM	LSI 13 (13q14)(sg)	RB1	Vysis	tumor	1;9
97	PDGFRB-cyto	MDS/MPN	5q33	PDGFRB	Vysis	tumor	onverdund
100	D13S31/13q34/CEP12	CLL	13q14.3 (so)/13q34 (sa)/ cep12 (sg)	D13S319/LAMP1	Vysis	tumor	1:1 cll panel

102	TCF3-PBX1-cyto	ALL	19p13.3 (sg)/1q23 (so)	TCF3/PBX1	Vysis	tumor	1;9
106	CEPX-CEPY-cyto	SCT	Xp11.1-q111.1 (sg)/Yp11.1q11.1(DYZ3) (s	CEPX/CEPY	Vysis	tumor	1;9
108	CEP8	MDS	8p11.1-q11.1 (D8Z2)(sg)	CEP8	Vysis	tumor	1;9
109	CEPY (sg)	MDS	cep Y (sg)	CEPY	Cytocell	tumor	3;7
110	TCL1 break apart	T-PLL	14q32,13	TCL1	Cytocell	tumor	onverdund
111	Evi1 tricolore (MECOM)	AML	3q26,2	EVI1 (MECOM)	Cytocell	tumor	onverdund
112	BIRC3/MALT1 DF t(11;18)	mzl	11q22 (sg)/18q21 (so)	BIRC3/MALT1	Vysis	tumor	1;9
113	JAK2 DC break apart	MDS/MPN	9p24.1	JAK2	Cytocell MP H2860	tumor	onverdund
114	CHIC2/FIP1L1/PDGFR A so/sg/sa	HESCel/CMPD/eosinofilie	4q12	CHIC2-FIP1L1-PDGFR A	Cytocell MP H2170	tumor	onverdund